r/retatrutide GLP-3 R Lilly Prepares for Retatrutide FDA

One of these studies revealed no significant disparity in the incidence of adverse events between AOM and control cohorts

Following this, there have been two clinical phase 2 trials (SAR425899 and MEDI0382 also known as cotadutide) published evaluating GLP-1/glucagon receptor co-agonists

10.1016/s0006-8993(96)01347-9 39 DavidD

Cell (2017) This landmark Cell publication from Erasmus University Medical Center introduced FOXO4-DRI as a senolytic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 interaction

Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand